IONETIX Announces Targeted Alpha Therapy Manufacturing Center
News provided by
Share this article
Share this article
LANSING, Mich., March 16, 2021 /PRNewswire/ IONETIX, a leading cyclotron technology and isotope manufacturing company, has acquired a 10,300 sq. ft. facility in Lansing, MI for its new
Targeted Alpha Radionuclide Manufacturing Center. The company is in the process of equipping the site for full cGMP drug manufacturing capabilities including a 30 MeV cyclotron unit for alpha radionuclide production to support pre-clinical research, drug development, and early stage clinical trials. IONETIX is currently developing a 30MeV cyclotron utilizing the same proprietary cyclotron technology platform employed in their ION 12SC cyclotron.